NASDAQ:ABUS

Arbutus Biopharma Stock Forecast, Price & News

$4.35
+0.04 (+0.93 %)
(As of 09/17/2021 12:00 AM ET)
Add
Compare
Today's Range
$4.15
$4.37
50-Day Range
$2.65
$4.38
52-Week Range
$2.43
$5.87
Volume2.83 million shs
Average Volume2.10 million shs
Market Capitalization$431.35 million
P/E RatioN/A
Dividend YieldN/A
Beta2.9
30 days | 90 days | 365 days | Advanced Chart
Receive ABUS News and Ratings via Email

Sign-up to receive the latest news and ratings for Arbutus Biopharma and its competitors with MarketBeat's FREE daily newsletter.


Arbutus Biopharma logo

About Arbutus Biopharma

Arbutus Biopharma Corp. is a biopharmaceutical company. It engages in discovering, developing and commercializing a cure for patients suffering from chronic Hepatitis B virus infection. The company was founded in 2007 and is headquartered in Warminster, PA.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Social Links


MarketRank

Overall MarketRank

1.76 out of 5 stars

Medical Sector

811th out of 1,350 stocks

Pharmaceutical Preparations Industry

401st out of 664 stocks

Analyst Opinion: 3.4Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Arbutus Biopharma (NASDAQ:ABUS) Frequently Asked Questions

Is Arbutus Biopharma a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arbutus Biopharma in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Arbutus Biopharma stock.
View analyst ratings for Arbutus Biopharma
or view top-rated stocks.

What stocks does MarketBeat like better than Arbutus Biopharma?

Wall Street analysts have given Arbutus Biopharma a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Arbutus Biopharma wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Arbutus Biopharma?

Arbutus Biopharma saw a decrease in short interest in the month of August. As of August 13th, there was short interest totaling 4,150,000 shares, a decrease of 26.2% from the July 29th total of 5,620,000 shares. Based on an average daily trading volume, of 1,650,000 shares, the short-interest ratio is currently 2.5 days. Currently, 5.2% of the company's stock are sold short.
View Arbutus Biopharma's Short Interest
.

When is Arbutus Biopharma's next earnings date?

Arbutus Biopharma is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Arbutus Biopharma
.

How were Arbutus Biopharma's earnings last quarter?

Arbutus Biopharma Co. (NASDAQ:ABUS) issued its earnings results on Wednesday, August, 4th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.21) by $0.02. The biopharmaceutical company had revenue of $2.33 million for the quarter, compared to the consensus estimate of $2.07 million.
View Arbutus Biopharma's earnings history
.

How has Arbutus Biopharma's stock price been impacted by Coronavirus (COVID-19)?

Arbutus Biopharma's stock was trading at $2.58 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ABUS shares have increased by 68.6% and is now trading at $4.35.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for ABUS?

4 Wall Street analysts have issued 1 year price targets for Arbutus Biopharma's stock. Their forecasts range from $5.00 to $10.00. On average, they expect Arbutus Biopharma's stock price to reach $6.75 in the next twelve months. This suggests a possible upside of 55.2% from the stock's current price.
View analysts' price targets for Arbutus Biopharma
or view top-rated stocks among Wall Street analysts.

Who are Arbutus Biopharma's key executives?

Arbutus Biopharma's management team includes the following people:
  • William H. Collier, President, Chief Executive Officer & Director
  • David C. Hastings, Chief Financial & Accounting Officer
  • Michael J. Sofia, Chief Scientific Officer
  • Elizabeth Howard, Secretary, Chief Compliance Officer & EVP
  • Michael J. McElhaugh, Chief Business Officer

What is Mark J. Murray's approval rating as Arbutus Biopharma's CEO?

6 employees have rated Arbutus Biopharma CEO Mark J. Murray on Glassdoor.com. Mark J. Murray has an approval rating of 22% among Arbutus Biopharma's employees. This puts Mark J. Murray in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Arbutus Biopharma's key competitors?

What other stocks do shareholders of Arbutus Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arbutus Biopharma investors own include Ballard Power Systems (BLDP), Chiasma (CHMA), Bausch Health Companies (BHC), Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), GW Pharmaceuticals (GWPH), Inovio Pharmaceuticals (INO), Alibaba Group (BABA), TherapeuticsMD (TXMD) and Novavax (NVAX).

What is Arbutus Biopharma's stock symbol?

Arbutus Biopharma trades on the NASDAQ under the ticker symbol "ABUS."

Who are Arbutus Biopharma's major shareholders?

Arbutus Biopharma's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.88%), Vanguard Group Inc. (3.77%), Geode Capital Management LLC (1.30%), State Street Corp (1.17%), Point72 Asset Management L.P. (1.01%) and Northern Trust Corp (0.73%).
View institutional ownership trends for Arbutus Biopharma
.

Which major investors are selling Arbutus Biopharma stock?

ABUS stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Morgan Stanley, Cubist Systematic Strategies LLC, Qube Research & Technologies Ltd, SG3 Management LLC, Point72 Asset Management L.P., Citigroup Inc., and Credit Suisse AG.
View insider buying and selling activity for Arbutus Biopharma
or view top insider-selling stocks.

Which major investors are buying Arbutus Biopharma stock?

ABUS stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., State Street Corp, Vanguard Group Inc., Geode Capital Management LLC, Northern Trust Corp, Deutsche Bank AG, Group One Trading L.P., and Nuveen Asset Management LLC.
View insider buying and selling activity for Arbutus Biopharma
or or view top insider-buying stocks.

How do I buy shares of Arbutus Biopharma?

Shares of ABUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arbutus Biopharma's stock price today?

One share of ABUS stock can currently be purchased for approximately $4.35.

How much money does Arbutus Biopharma make?

Arbutus Biopharma has a market capitalization of $431.35 million and generates $6.91 million in revenue each year. The biopharmaceutical company earns $-63,740,000.00 in net income (profit) each year or ($1.00) on an earnings per share basis.

How many employees does Arbutus Biopharma have?

Arbutus Biopharma employs 77 workers across the globe.

When was Arbutus Biopharma founded?

Arbutus Biopharma was founded in 1992.

What is Arbutus Biopharma's official website?

The official website for Arbutus Biopharma is www.arbutusbio.com.

Where are Arbutus Biopharma's headquarters?

Arbutus Biopharma is headquartered at 701 VETERANS CIRCLE, WARMINSTER PA, 18974.

How can I contact Arbutus Biopharma?

Arbutus Biopharma's mailing address is 701 VETERANS CIRCLE, WARMINSTER PA, 18974. The biopharmaceutical company can be reached via phone at (267) 469-0914 or via email at [email protected].


This page was last updated on 9/19/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.